Geneseeq, Author at Geneseeq Technology Inc. | A Precision Oncology Company

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

0 Comments2 Minutes

November 15, 2022

Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM

0 Comments4 Minutes

November 3, 2022

Geneseeq study evaluates the clinical value of cell-free DNA 5’-end motif profile in the prediction of pathological complete response for LARC patients after neoadjuvant chemoradiotherapy

0 Comments3 Minutes

October 18, 2022

Geneseeq study highlights ctDNA monitoring clinical value in colorectal cancer patients resistant to BRAF/EGFR-targeted therapy

0 Comments3 Minutes

October 12, 2022

Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq

0 Comments4 Minutes

September 7, 2022

Geneseeq to present five posters at European Society for Medical Oncology 2022

0 Comments6 Minutes

August 3, 2022

GENESEEQ AND COLLABORATORS SHARE NEW FINDINGS AT WORLD CONFERENCE ON LUNG CANCER 2022

0 Comments10 Minutes

July 19, 2022

Geneseeq, Brazilian Hospital Partner on Co-establishment of In-house NGS Lab

0 Comments3 Minutes

July 5, 2022

Geneseeq and collaborators publish new findings from DECIPHER series, exploring single cfDNA feature-based machine learning model for lung cancer early detection

0 Comments3 Minutes

June 13, 2022

Geneseeq Multicancer Early Detection Study Yields Promising Results

0 Comments3 Minutes